Treatment Patterns and Clinical Outcomes in Patients with HR+/HER2- and HR+/HER2+ Metastatic Breast Cancer in an Integrated Health Care SystemThis is an observational, retrospective cohort study of patients diagnosed with HR+/HER2 - and HR+/HER2+ metastatic breast cancer (mBC) who initiated first-line systemic therapy in the metastatic setting. Study aims are: 1) Among HR+/HER2- mBC patients diagnosed from 2015-2020, describe demographic and clinical characteristics, treatment characteristics, and real-world progression-free survival. 2) Among HR+/HER2+ mBC patients diagnosed from 2012-2020, describe demographic and clinical characteristics, treatment characteristics, and progression-free survival and overall survival. 3) Identify demographic and clinical factors associated with first- and second-line treatment receipt (HR+/HER2-), treatment selection (HR+/HER2+), and their clinical outcomes.
Investigator: Kwan, Marilyn
Funder: Pfizer Inc.